(Q36661852)

15 August 2017

CNS vasculitis in a patient with MS on daclizumab monotherapy (English)

1 reference

15 August 2017

Joan Ohayon

1

1 reference

15 August 2017

Unsong Oh

2

1 reference

15 August 2017

Nancy Richert

3

1 reference

15 August 2017

Jayne Martin

4

1 reference

15 August 2017

Alexander Vortmeyer

5

1 reference

15 August 2017

Henry McFarland

6

1 reference

15 August 2017

Bibiana Bielekova

7

1 reference

15 August 2017

language of work or name

English

0 references

publication date

9 January 2013

1 reference

15 August 2017

1 reference

15 August 2017

80

1 reference

15 August 2017

5

1 reference

15 August 2017

453-457

1 reference

Intrathecal effects of daclizumab treatment of multiple sclerosis

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3590053

A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3590053

An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3590053

Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3590053

Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3590053

Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3590053

Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3590053

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3590053

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3590053

Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody

20 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23303850

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1212/WNL.0B013E31827F0F42

1 reference

15 August 2017

1 reference

15 August 2017

PubMed publication ID

23303850

1 reference